• Neurology

FDA Approves Oveporexton for Narcolepsy Type 1

In a historic milestone for sleep medicine and neurological care, the FDA officially approved oveporexton.The Breakthrough: Developed by pharmaceutical innovators, this is the first oral orexin receptor 2 agonist designed to directly treat the core biological cause of Narcolepsy Type 1. Why It Matters: Traditional treatments only masked symptoms (like excessive daytime fatigue). This drug targets the underlying chemical deficiency in the brain, radically shifting how doctors approach sleep-wake cycle disorders.